SCHEMBL706559

SCHEMBL706559

O=C(Nc1cc[nH]n1)c1c(F)cccc1F

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
JAK2 O60674 2/20 0.51
JAK1 P23458 2/20 0.51
TYK2 P29597 2/20 0.51
HTT P42858 1/20 0.51
NOD2 Q9HC29 1/20 0.51
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
CYP1A2 P05177 1/20 0.50
LMNA P02545 1/20 0.48
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 2/20 0.42
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
CCNA2 P20248 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29164565 0.90 MEN1 (0.51) MEN1KMT2AJAK2JAK1TYK2
SCHEMBL756390 0.83 NPC1 (0.57) MEN1KMT2AHTTRAB9ANPC1
SCHEMBL754986 0.81 RAB9A (0.52) KMT2AJAK2JAK1TYK2RAB9A
SCHEMBL29164888 0.81 TYK2 (0.42) MEN1KMT2ATYK2HTTRAB9A
SCHEMBL7163550 0.80 MEN1 (0.66) MEN1KMT2ARAB9ANPC1CYP1A2
SCHEMBL29164630 0.79 L3MBTL1 (0.43) MEN1KMT2AJAK2JAK1TYK2
SCHEMBL30822650 0.79 L3MBTL1 (0.43) MEN1KMT2AJAK2JAK1TYK2
SCHEMBL7175136 0.78 CYP1A2 (0.58) RAB9ACYP1A2LMNAALDH1A1TP53
SCHEMBL14319835 0.78 MEN1 (1.00) MEN1KMT2AJAK2JAK1TYK2
SCHEMBL29164555 0.76 L3MBTL1 (0.43) MEN1KMT2AJAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116194439-B SOCE inhibitors and therapeutic uses thereof 国家医疗保健研究所 2025-04-08 CN disclosed
US-20240116876-A1 SOCE Inhibitors and Therapeutic Uses Thereof Institut National de la Santé et de la Recherche Médicale (FR) 2024-04-11 US disclosed
CN-116194439-A SOCE inhibitors and therapeutic uses thereof 国家医疗保健研究所 2023-05-30 CN disclosed
EP-4157822-A1 SOCE INHIBITORS AND THERAPEUTIC USES THEREOF Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2023-04-05 EP disclosed
WO-2021233994-A1 SOCE INHIBITORS AND THERAPEUTIC USES THEREOF INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-11-25 WO disclosed
EP-3912972-A1 SOCE INHIBITORS AND THERAPEUTIC USES THEREOF Centre Hospitalier Régional et Universitaire de Brest (FR) 2021-11-24 EP disclosed
US-8399436-B2 N-pyrazolyl carboxamides as CRAC channel inhibitors GLAXO GROUP LIMITED (GB) 2013-03-19 US disclosed
US-8399436-B2 N-pyrazolyl carboxamides as CRAC channel inhibitors GLAXO GROUP LIMITED (GB) 2013-03-19 US disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 US disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 US disclosed
EP-2421835-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS Glaxo Group Limited (GB) 2012-02-29 EP disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 WO disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 WO disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116876-A1 SOCE Inhibitors and Therapeutic Uses Thereof STIM1, ORAI1, STIM2 MEN1 1936/4885KMT2A 4679/4885JAK2 1526/4885
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS ORAI1, TRPV1, CACNA1E MEN1 2873/4885KMT2A 3401/4885JAK2 2500/4885
US-20100273744-A1 COMPOUNDS LTC4S, HRH4, HRH2 MEN1 3849/4885KMT2A 1734/4885JAK2 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.